Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib for Epistaxis in HHT
NCT03850730Phase 2Not yet recruiting
- Sponsor
- Cure HHT
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in hereditary hemorrhagic telangiectasia (HHT), sponsored by Cure HHT. Primary endpoint: Percent change in epistaxis duration. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
pazopanib
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT03850730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850730.